Continuing Pharmacy Education / CE Master List / NKOTB: 2025 Updates on Management of Hypertension in Adults – RECORDED WEBINAR
Please use this button to register in our system as a new user, or to purchase a CE Activity.
For free CE's, returning users can simply click the "TAKE TEST/EVALUATION" button on the right.
Please use this button when you have completed the CE Activity and are ready to take the quiz and complete the evaluation.

NKOTB: 2025 Updates on Management of Hypertension in Adults – RECORDED WEBINAR

This course is a recorded (home study version) of CE Finale 2025: Doppelgangers, Imposters, and New Kids
on the Block

Learning Objectives

  • Review the 2025 hypertension guidelines
  • Compare the updated recommendations to the prior guidelines
  • Review the evidence supporting the guideline changes

Activity Release Dates

Released:  December 19, 2025
Expires:  December 19, 2028

Course Fee

$17 Pharmacist

ACPE UAN Codes

 0009-0000-25-064-H01-P

Session Code

25RW64-UMH45

Accreditation Hours

1.0 hours of CE

Accreditation Statement

The University of Connecticut School of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Pharmacists and Pharmacy Technicians are eligible to participate in this application-based activity and will receive 1.0 CE Hour  for completing the activity  (ACPE UAN 0009-0000-25-064-H01-P), passing the quiz with a grade of 70% or better, and completing an online evaluation. Statements of credit are available via the CPE Monitor online system and your participation will be recorded with CPE Monitor within 72 hours of submission.

Grant Funding

There is no grant funding for this activity.

Faculty

William L. Baker, PharmD, FCCP, FACC, FHFSA
Clinical Professor
UConn School of Pharmacy
Storrs, CT

    

Faculty Disclosure

  • Dr. Baker doesn't have any relationships with ineligible companies.

 

Disclaimer

The material presented here does not necessarily reflect the views of The University of Connecticut School of Pharmacy or its co-sponsor affiliates. These materials may discuss uses and dosages for therapeutic products, processes, procedures and inferred diagnoses that have not been approved by the United States Food and Drug Administration. A qualified health care professional should be consulted before using any therapeutic product discussed. All readers and continuing education participants should verify all information and data before treating patients or employing any therapies described in this continuing education activity.

Content

Posttest

  1. According to the 2025 guidelines, which of the following represents the blood pressure goal for adults with confirmed hypertension?
    1. SBP < 120 mmHg & DBP < 70 mmHg
    2. SBP < 130 mmHg & DBP < 80 mmHg
    3. SBP < 140 mmHg & DBP < 90 mmHg
  2. According to the 2025 Hypertension guidelines, which of the following would be an appropriate initial combination to start in a patient with stage 2 hypertension?
    1. Lisinopril + amlodipine***
    2. Valsartan + chlorthalidone
    3. Verapamil + hydrochlorothiazide
  3. When using the PREVENT equation to estimate 10-year cardiovascular disease risk, what is the threshold above which a patient with hypertension should be initiated on drug therapy medications to lower their blood pressure?
    1. >5%
    2. >7.5%
    3. >10%
  4. Which of the following represents a new recommendation in the 2025 Hypertension guideline that was not in the previous (2017) version?
    1. Start initial combination therapy for anyone with stage 2 hypertension
    2. ACEi/ARB, CCB, and diuretics are first-line therapies unless contraindicated
    3. Individuals without BP ≥130/80 mmHg, no CVD, and a 10-year CVD risk ≥7.5% should start antihypertensive medication
  5. Which of the following is most accurate about emerging drug treatments for hypertension?
    1. Emerging drug therapies, while effective, have concerns for hyperkalemia and hypotension
    2. Trials have exclusively been conducted in newly-diagnosed adult patients
    3. Mechanisms of emerging drugs have targeted attenuation of the sympathetic nervous system